Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Buy” from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have earned an average recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $43.00.

Several research analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective on the stock. HC Wainwright assumed coverage on shares of Bicara Therapeutics in a research note on Friday, December 6th. They set a “buy” rating and a $42.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating on the stock. Finally, Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target on the stock.

Bicara Therapeutics Trading Up 1.9 %

Shares of BCAX stock opened at $12.11 on Monday. Bicara Therapeutics has a 1 year low of $11.56 and a 1 year high of $28.09. The company has a fifty day simple moving average of $18.11.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BCAX. SG Americas Securities LLC bought a new stake in Bicara Therapeutics in the 4th quarter valued at about $147,000. Cinctive Capital Management LP bought a new stake in Bicara Therapeutics in the 3rd quarter valued at about $229,000. Barclays PLC bought a new stake in Bicara Therapeutics in the 3rd quarter valued at about $255,000. Jane Street Group LLC bought a new stake in Bicara Therapeutics in the 3rd quarter valued at about $309,000. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in Bicara Therapeutics in the 3rd quarter valued at about $358,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.